From your perspective as an investigator in the brensocatib trials, what do you feel are the most important translation take-aways about the deployment of this novel neutrophil-and-inflammation-targeting therapy at the front lines of NCFBE care?

Professor Michael Loebinger, MA, FRCP, PhD

Director of the Lung DivisionaClinical Director of Laboratory MedicineaDeputy Medical DirectorConsultant Respiratory MedicineRoyal Brompton & Harefield HospitalsProfessor of Practice (Respiratory Medicine)National Heart and Lung InstituteImperial ...